Dynamic changes of angiopoietins and endothelial nitric oxide supply during fluid resuscitation for major gyn-oncological surgery: a prospective observation.
Angiopoietins
Fluid resuscitation
Microvascular reactivity
Nitric oxide
eNOS
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
31 01 2020
31 01 2020
Historique:
received:
02
11
2019
accepted:
22
01
2020
entrez:
2
2
2020
pubmed:
2
2
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Despite goal-directed hemodynamic therapy, vascular function may deteriorate during surgery for advanced abdominal tumor masses. Fluid administration has been shown to be associated with distinct changes in serum levels of functional proteins. We sought to determine how serum total protein and angiopoietin (ANG) levels change during major abdominal tumor surgery. In addition, ex vivo endothelial nitric oxide synthase (eNOS) activation as well as NO bioavailability in vivo were assessed. 30 patients scheduled for laparotomy for late-stage ovarian or uterine cancer were prospectively included. Advanced hemodynamic monitoring as well as protocol-driven goal-directed fluid optimization were performed. Total serum protein, ANG-1, -2, and soluble TIE2 were determined pre-, intra-, and postoperatively. Phosphorylation of eNOS was assessed in microvascular endothelial cells after incubation with patient serum, and microvascular reactivity was determined in vivo by near-infrared spectroscopy and arterial vascular occlusion. Cardiac output as well as preload gradually decreased during surgery and were associated with a median total fluid intake of 12.8 (9.7-15.4) mL/kg*h and a postoperative fluid balance of 6710 (4113-9271) mL. Total serum protein decreased significantly from baseline (66.5 (56.4-73.3) mg/mL) by almost half intraoperatively (42.7 (36.8-51.5) mg/mL, p < 0.0001) and remained at low level. While ANG-1 showed no significant dilutional change (baseline: 12.7 (11.9-13.9) ng/mL, postop.: 11.6 (10.8 -13.5) ng/mL, p = 0.06), serum levels of ANG-2 were even increased postoperatively (baseline: 2.2 (1.6-2.6) ng/mL vs. postop.: 3.4 (2.3-3.8) ng/mL, p < 0.0001), resulting in a significant shift in ANG-2 to ANG-1 ratio. Ex vivo phosphorylation of eNOS was decreased depending on increased ANG-2 levels and ANG-2/1 ratio (Spearman r = - 0.37, p = 0.007). In vivo, increased ANG-2 levels were associated with impaired capillary recruitment and NO bioavailability (Spearman r = - 0.83, p = 0.01). Fluid resuscitation-associated changes in serum vascular mediator profile during abdominal tumor surgery were accompanied by impaired eNOS activity ex vivo as well as reduced NO bioavailability in vivo. Our results may explain disturbed microvascular function in major surgery despite goal-directed hemodynamic optimization.
Sections du résumé
BACKGROUND
Despite goal-directed hemodynamic therapy, vascular function may deteriorate during surgery for advanced abdominal tumor masses. Fluid administration has been shown to be associated with distinct changes in serum levels of functional proteins. We sought to determine how serum total protein and angiopoietin (ANG) levels change during major abdominal tumor surgery. In addition, ex vivo endothelial nitric oxide synthase (eNOS) activation as well as NO bioavailability in vivo were assessed.
METHODS
30 patients scheduled for laparotomy for late-stage ovarian or uterine cancer were prospectively included. Advanced hemodynamic monitoring as well as protocol-driven goal-directed fluid optimization were performed. Total serum protein, ANG-1, -2, and soluble TIE2 were determined pre-, intra-, and postoperatively. Phosphorylation of eNOS was assessed in microvascular endothelial cells after incubation with patient serum, and microvascular reactivity was determined in vivo by near-infrared spectroscopy and arterial vascular occlusion.
RESULTS
Cardiac output as well as preload gradually decreased during surgery and were associated with a median total fluid intake of 12.8 (9.7-15.4) mL/kg*h and a postoperative fluid balance of 6710 (4113-9271) mL. Total serum protein decreased significantly from baseline (66.5 (56.4-73.3) mg/mL) by almost half intraoperatively (42.7 (36.8-51.5) mg/mL, p < 0.0001) and remained at low level. While ANG-1 showed no significant dilutional change (baseline: 12.7 (11.9-13.9) ng/mL, postop.: 11.6 (10.8 -13.5) ng/mL, p = 0.06), serum levels of ANG-2 were even increased postoperatively (baseline: 2.2 (1.6-2.6) ng/mL vs. postop.: 3.4 (2.3-3.8) ng/mL, p < 0.0001), resulting in a significant shift in ANG-2 to ANG-1 ratio. Ex vivo phosphorylation of eNOS was decreased depending on increased ANG-2 levels and ANG-2/1 ratio (Spearman r = - 0.37, p = 0.007). In vivo, increased ANG-2 levels were associated with impaired capillary recruitment and NO bioavailability (Spearman r = - 0.83, p = 0.01).
CONCLUSIONS
Fluid resuscitation-associated changes in serum vascular mediator profile during abdominal tumor surgery were accompanied by impaired eNOS activity ex vivo as well as reduced NO bioavailability in vivo. Our results may explain disturbed microvascular function in major surgery despite goal-directed hemodynamic optimization.
Identifiants
pubmed: 32005259
doi: 10.1186/s12967-020-02236-9
pii: 10.1186/s12967-020-02236-9
pmc: PMC6995240
doi:
Substances chimiques
Angiopoietin-2
0
Angiopoietins
0
Nitric Oxide
31C4KY9ESH
NOS3 protein, human
EC 1.14.13.39
Nitric Oxide Synthase Type III
EC 1.14.13.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Références
Curr Opin Hematol. 2017 Sep;24(5):432-438
pubmed: 28582314
Anesthesiology. 2019 May;130(5):825-832
pubmed: 30789364
Acta Anaesthesiol Scand. 2015 Nov;59(10):1303-10
pubmed: 26079310
J Pharmacol Exp Ther. 2005 Aug;314(2):738-44
pubmed: 15870388
Pharmacol Res. 2014 Feb;80:43-51
pubmed: 24407281
Ann R Coll Surg Engl. 2009 Nov;91(8):703-7
pubmed: 19909614
Ann Surg. 2016 Jul;264(1):73-80
pubmed: 27275778
Crit Care. 2015 Sep 04;19:316
pubmed: 26337035
Rev Esp Anestesiol Reanim. 2016 Mar;63(3):149-58
pubmed: 26318757
J Cell Physiol. 2008 Feb;214(2):491-503
pubmed: 17960565
Shock. 2006 Aug;26(2):115-21
pubmed: 16878017
Eur J Surg Oncol. 2017 Jun;43(6):1013-1027
pubmed: 27727026
Crit Care. 2009;13 Suppl 5:S6
pubmed: 19951390
JAMA Surg. 2017 Dec 1;152(12):1156-1160
pubmed: 28832866
Crit Care. 2010;14(3):R89
pubmed: 20482750
Methods Mol Biol. 1994;32:5-8
pubmed: 7951748
Crit Care Resusc. 2018 Sep;20(3):198-208
pubmed: 30153782
Methods Mol Biol. 2014;1105:43-57
pubmed: 24623218
Science. 1997 Jul 4;277(5322):55-60
pubmed: 9204896
Mediators Inflamm. 2015;2015:418290
pubmed: 26770016
Pflugers Arch. 2016 Jul;468(7):1125-1137
pubmed: 27184745
Mediators Inflamm. 2019 Jul 17;2019:5263717
pubmed: 31396019
Biosci Rep. 2014 Aug 06;34(4):null
pubmed: 24993645
Gynecol Oncol. 2016 Oct 28;:null
pubmed: 28029449
Ann Clin Biochem. 1989 Jan;26 ( Pt 1):49-57
pubmed: 2472099
Eur J Anaesthesiol. 2010 Jun;27(6):555-61
pubmed: 20035228
Crit Care. 2019 Apr 11;23(1):117
pubmed: 30975180
Ann Thorac Surg. 2012 Jul;94(1):226-33
pubmed: 22571880
Crit Care. 2016 Mar 06;20:51
pubmed: 26951111
J Appl Physiol (1985). 2019 Jun 1;126(6):1646-1660
pubmed: 30998121
Crit Care. 2016 Apr 26;20(1):113
pubmed: 27117323
Circ Res. 2008 Feb 29;102(4):497-504
pubmed: 18096817
J Cardiothorac Vasc Anesth. 2013 Oct;27(5):845-52
pubmed: 23791494